The biotech and medtech sectors are buzzing with excitement in 2024, thanks to a wave of innovation and promising developments that have captured the attention of investors and industry experts alike. Groundbreaking advancements in diabetes treatments and a surge in mergers and acquisitions are driving a renaissance in the healthcare industry, fueled by cutting-edge technologies and a renewed focus on patient-centric solutions.
While many high-growth stocks in these sectors trade at premium valuations, there are still some hidden gems trading at relatively low prices that could potentially break out. This brings us to three biotech and medical technology firms that have consensus “buy” ratings from analysts, with projected upside of 119% or more to their mean price targets: Mind Medicine Inc. (MNMD), ReWalk Robotics Ltd. (LFWD), and BrainsWay Ltd. (BWAY).
